Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV PCA Hydromorphone vs Oral Opioid for Cancer Pain
NCT04785768Phase 3Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2021
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydromorphone in cancer pain (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: 3-day average Numeric Rating Scale up to 4 days. Started Jul 2021; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT04785768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785768.